Letters
HRT and cardiovascular events
Study had insufficient power to investigate safety
BMJ 2012; 345 doi: https://doi.org/10.1136/bmj.e8146 (Published 03 December 2012) Cite this as: BMJ 2012;345:e8146- Jacques E Rossouw, medical officer1,
- JoAnn E Manson, professor of medicine2,
- Andrew M Kaunitz, professor of obstetrics and gynecology3,
- Marcia L Stefanick, professor of medicine4
- 1National Heart, Lung, and Blood Institute, Bethesda, MD, USA
- 2Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USA
- 3University of Florida College of Medicine-Jacksonville, FL, USA
- 4Stanford University School of Medicine, Stanford, CA, USA
- rossouwj{at}nih.gov
There are several concerns about the robustness of Schierbeck and colleagues’ findings.1 The open label design means that the trial could not control for placebo effect, and knowledge of active treatment could have led to differential ascertainment of outcomes.
The composite outcome of mortality, myocardial infarction, and heart failure was not prespecified in the design paper, …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.